1. Introduction
===============

Soft corals of the genue *Sinularia* have been discovered to be a rich source of terpenes \[[@B1-marinedrugs-10-01572]\]. Previously, we discovered a 9,11-secosterol \[[@B2-marinedrugs-10-01572]\] and diterpenes-related compounds \[[@B3-marinedrugs-10-01572],[@B4-marinedrugs-10-01572]\] from the soft coral *Sinularia lochmodes* collected off the coast of southern Taiwan. Our current chemical investigation of the soft coral *S. lochmodes*, collected from the northeastern coast of Taiwan, has led to the isolation of six new aromadendrane-type \[[@B5-marinedrugs-10-01572],[@B6-marinedrugs-10-01572],[@B7-marinedrugs-10-01572]\] sesquiterpenoids lochmolins A--F (**1**--**6**), and a new germacrane \[[@B8-marinedrugs-10-01572]\] sesquiterpenoid lochmolin G (**7**) ([Chart 1](#marinedrugs-10-01572-f005){ref-type="fig"}). The relative structures of the new metabolites were established by extensive spectroscopic analysis. The ability of **1**--**7** to inhibit up-regulation of the pro-inflammatory iNOS (inducible nitric oxide synthase) and COX-2 (cyclooxygenase-2) proteins in LPS (lipopolysaccharide)-stimulated RAW264.7 macrophage cells was also evaluated.

![Structures of metabolites **1**--**7**.](marinedrugs-10-01572-g005){#marinedrugs-10-01572-f005}

2. Results and Discussion
=========================

Lochmolin A (**1**) was isolated as a colorless oil. Its molecular formula, C~15~H~22~O~2~, was established by HREIMS (*m/z* 234.1620, \[M\]^+^), implying five degrees of unsaturation. The ^13^C NMR spectral data of **1** ([Table 1](#marinedrugs-10-01572-t001){ref-type="table"}), showed the presence of 15 carbon atoms, including three methyls (δ~C~ 28.5, 24.8, and 16.2) and two quaternary sp^3^oxycarbons (δ~C~ 89.3 and 83.1), as assigned by the DEPT spectrum, suggesting the oxygenated sesquiterpenoid nature of **1**. The NMR signals ([Table 1](#marinedrugs-10-01572-t001){ref-type="table"} and [Table 2](#marinedrugs-10-01572-t002){ref-type="table"}) observed at δ~C~ 112.7 (CH~2~) and 151.5 (C), δ~H~ 5.02 and 4.89 (each 1H, s) showed the presence of one 1,1-disubstituted double bond. Thus, the tetracyclic structure of **1** was revealed. In the ^1^H-^1^H COSY spectrum it was possible to identify two different structural units, which were assembled with the assistance of an HMBC experiment. Key HMBC correlations of H~2~-2 to C-1, C-3, C-4 and C-5; H~3~-12 to C-6, C-7, C-11 and C-13; H~3~-13 to C-6, C-7, C-11 and C-12; H~2~-14 to C-1, C-9 and C-10; H~3~-15 to C-3, C-4 and C-5 permitted the establishment of the aromadendrane-type skeleton of **1** ([Figure 1](#marinedrugs-10-01572-f001){ref-type="fig"}). Furthermore, the two additional oxygen atoms could be used to form an endoperoxide bridge in the cyclopentane moiety of the molecule from the downfield chemical shifts of the sp^3^ carbons C-1 (δ 89.3, C) and C-4 (δ 83.1, C). The presence of a cyclopropane was further confirmed by the upfield chemical shifts of H-6 (δ 0.08) and H-7 (δ 0.54).
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###### 

^13^C NMR spectroscopic data for compounds **1**--**7**.

        1       2      3       4       5       6       7
  ----- ------- ------ ------- ------- ------- ------- -------
  1     89.3    47.3   150.1   101.1   96.8    155.2   41.1
  2     36.0    23.4   125.2   29.6    29.1    117.3   23.4
  3     38.9    37.8   45.3    39.0    39.6    45.1    40.8
  4     83.1    79.3   82.2    81.7    81.0    82.2    73.0
  5     56.2    49.9   52.6    55.2    57.3    53.8    143.1
  6     27.4    25.1   27.4    26.6    21.4    27.2    128.4
  7     23.0    26.2   27.0    24.2    27.6    27.4    57.9
  8     20.9    20.1   18.8    20.6    25.2    20.2    24.7
  9     31.4    40.3   38.3    33.1    34.1    43.4    129.5
  10    151.5   80.4   83.0    147.1   150.7   73.9    131.9
  11    18.4    19.0   20.3    18.5    19.9    19.0    71.9
  12    28.5    28.9   28.5    28.4    28.6    28.3    26.8
  13    16.2    16.4   16.0    16.0    15.7    16.0    26.9
  14    112.7   25.7   23.0    116.2   113.3   27.3    16.6
  15    24.8    18.8   22.9    24.3    27.6    22.4    23.4
  OEt           55.2                                   
        16.3                                           

marinedrugs-10-01572-t002_Table 2

###### 

^1^H NMR spectral data for compounds **1**--**4**.

           1                      2                     3                                  4
  -------- ---------------------- --------------------- ---------------------------------- ---------------------
  1                               1.05 m                                                   
  2        2.01 m2.45 m           1.70 m1.80 m          5.66 d (3.0)                       2.19 m2.46 m
  3        1.95 m2.05 m           1.62 m1.72 m          2.27 dd (17.0, 3.0)2.61 d (17.0)   1.91 m1.97 m
  5        1.77 d (12.0) *^a^*    2.38 dd (11.0, 5.5)   2.31 d (11.0)                      1.68 d (11.5)
  6        0.08 dd (12.0, 10.0)   0.64 m                0.27 dd (11.0, 9.5)                0.19 dd (11.5, 9.0)
  7        0.54 dd (17.0, 10.0)   0.67 m                0.53 m                             0.58 m
  8        1.48 m1.87 m           0.89 m1.86 m          1.46 m1.65 m                       1.40 m1.80 m
  9        2.30 m2.65 m           1.48 m1.68 m          1.64 m1.92 dd (14.5, 5.5)          2.35 m2.63 m
  12       1.00 s                 1.05 s                1.02 s                             1.02 s
  13       1.06 s                 0.97 s                1.12 s                             1.04 s
  14       4.89 s5.02 s           1.24 s                1.49 s                             5.08 s5.14 s
  15       1.30 s                 1.05 s                1.40 s                             1.27 s
  16                              3.40 m3.44 m                                             
  17                              1.12 t (7.0)                                             
  10-OOH                                                7.64 s                             

*^a^* *J* values (Hz) in parentheses.

![Selected ^1^H-^1^H COSY (▬) and HMBC (→) correlations of **1**--**4** and **7**.](marinedrugs-10-01572-g001){#marinedrugs-10-01572-f001}

The relative configurations of five chiral centers at C-1, C-4, C-5, C-6, and C-7 in **1** were elucidated by NOE analysis ([Figure 2](#marinedrugs-10-01572-f002){ref-type="fig"}). It was found that H-6 showed NOE correlations with H-7, H~3~-12, and H~3~-15; H-7 (δ 0.54) showed NOE correlations with H~3~-12; and H-5 (δ 1.77) showed NOE correlations with H~3~-13. Thus H-6, H-7, and H~3~-15 were assumed to be positioned on the α face, and H-5 was assumed to be positioned on the β face. On the basis of these results, lochmolin A (**1**) was found to possess the (1*R\**,4*S\**,5*R\**,6*R\**,7*R\**) configuration.

![Key NOESY correlations for **1**--**3**.](marinedrugs-10-01572-g002){#marinedrugs-10-01572-f002}

Lochmolin B (**2**) was obtained as a colorless oil. HRESIMS showed the molecular formula C~17~H~30~O~2~, requiring three degrees of unsaturation. The IR spectrum suggested the presence of hydroxy group (3437 cm^−1^). The 3H triplet appearing at δ 1.12 (*J* = 7.0 Hz) in the ^1^H NMR spectrum and the methylene carbon signal at δ 55.2 in the ^13^C NMR spectrum were ascribable to an ethoxy group. Comparison of the NMR data ([Table 1](#marinedrugs-10-01572-t001){ref-type="table"}) of **2** with those of **1** also showed the aromadendrane skeleton of **2**. In the 2D NMR spectra, including ^1^H-^1^H COSY and HMBC ([Figure 1](#marinedrugs-10-01572-f001){ref-type="fig"}), three segregate consecutive proton spin systems, H-1 to H~2~-3, H-5 to H~2~-9, and CH~2~ to CH~3~ of an ethoxy group, were found in the ^1^H-^1^H COSY spectrum. The detailed analysis of HMBC correlations further established the planar structure of **2**. The relative structure of **2** was elucidated by the analysis of NOE correlations, as shown in [Figure 2](#marinedrugs-10-01572-f002){ref-type="fig"}. It was found that H-6 (δ 0.64, m) showed NOE interactions with H-1 (δ 1.05, m), H-7 (δ 0.67, m), H~3~-12 (δ 1.05, s) and H~3~-15 (δ 1.05, s), and H-7 (δ 0.67, m) showed NOE correlations with H-8α (δ 1.86, m) and H~3~-12 (δ 1.05, s); therefore, assuming the α-orientation of H-1, all of H-6, H-7, H~3~-12 and H~3~-15 should also be positioned on the α face. One of the methylene protons at C-9 (δ 1.68, m) exhibited NOE correlations with H-8α (δ 1.86, m) and was characterized as H-9α, while the other (δ 1.48, m) was assigned as H-9β. NOE correlations observed between H-9β and H~3~-14, and H-5 with both H~3~-13 (δ 0.97, s) and protons of OCH~2~, reflected the β-orientation of H-5 and H~3~-14. On the basis of the above findings ([Figure 2](#marinedrugs-10-01572-f002){ref-type="fig"}), the relative structure of lochmolin B (**2**) was determined.

The HRESIMS spectrum of lochmolin C (**3**) exhibited a molecular ion peak at *m/z* 275.1622 (\[M + Na\]^+^), consistent with the molecular formula C~15~H~24~O~3~ and implying four degrees of unsaturation. The IR absorption of **3** also revealed the presence of hydroxy group (3437 cm^−1^). Comparison of the NMR data ([Table 1](#marinedrugs-10-01572-t001){ref-type="table"} and [Table 2](#marinedrugs-10-01572-t002){ref-type="table"}) of **3** with those of **2** showed the appearance of an additional trisubstituted double bond in **3**. The NMR chemical shifts for C-4 and C-10 of **3** (δ 82.2 and δ 83.0, respectively), were found to be shifted downfield in comparison with the analogous data of **2** (δ 79.3 and δ 80.4), suggesting that the 4-OEt and 10-OH of **2** might be replaced by the 4-OH and 10-OOH (δ 7.64, s) in **3**. This could be confirmed from the carbon shifts of both hydroxylated quaternary carbons C-4 (δ 82.2) and C-10 (δ 73.9) of **6** (latter discussed) which showed the identical chemical shift of C-4 of compound **3**. By analysis of 2D NMR spectra (HMQC, ^1^H-^1^H COSY, and HMBC), compound **3** was shown to possess the same molecular framework as that of **2**. Investigation of the NOESY spectrum of **3** ([Figure 2](#marinedrugs-10-01572-f002){ref-type="fig"}) revealed the NOE interactions of H-7 (δ 0.53, m) with H-8α (δ 1.65, m), H-8α with H-9α (δ 1.92, dd, *J* = 14.5, 5.5 Hz), and H-9α with H~3~-14 (δ 1.49, s), suggesting the α-orientation of H~3~-14. Further analysis of other NOE interactions revealed that **3** possessed the same relative configurations at C-4, C-5, C-6, and C-7 as those of **2**.

Lochmolin D (**4**) was also isolated as a colorless oil with a molecular formula of C~15~H~24~O~3~. The ESIMS and NMR spectroscopic data of **4** ([Table 1](#marinedrugs-10-01572-t001){ref-type="table"}) showed the presence of a hydroxy and hydroperoxy moiety \[δ 81.7 (C), and 101.1 (C)\]. Comparison of the NMR data of **4** with those **1** revealed that the two differences between both compounds were the replacement of the endoperoxide bridge moiety at C-1 and C-4 in **1** by the hydroxy at C-4 and the hydroperoxy at C-1 in **4**. The relative structure of **4** was elucidated by the analysis of NOE correlations, as shown in [Figure 3](#marinedrugs-10-01572-f003){ref-type="fig"}. It was found that H-6 (δ 0.19, dd, *J* = 11.5, 9.0 Hz) showed NOE interactions with H-7 (δ 0.58, m), H~3~-12 (δ 1.02, s), and H~3~-15 (δ 1.27, s), but not with H-5 (δ 1.68, d, *J* = 9.0 Hz); therefore, assuming an α-orientation of H-6, H-7 and H~3~-15 should also be positioned on the α face, and H-5 should be placed on the β face. One of the sp^3^methylene proton at C-2 (δ 2.19, m) exhibited NOE correlations with one of the sp^2^methylene proton at C-14 (δ 5.08, s), suggesting the β-orientation of 1-OOH by inspecting the molecular model of **4**. If the 1-OOH was placed on the α face as in the case of **5** (latter discussed), both protons at C-2 were found to exhibit NOE correlations with one of the sp^2^ proton at C-14 by molecular modeling study. On the basis of the above findings, the relative structure of **4** was determined.

![Key NOESY correlations for **4**--**6**.](marinedrugs-10-01572-g003){#marinedrugs-10-01572-f003}

HRESIMS and NMR spectroscopic data ([Table 1](#marinedrugs-10-01572-t001){ref-type="table"} and [Table 3](#marinedrugs-10-01572-t003){ref-type="table"}) revealed that lochmolin E (**5**) has the same molecular formula, C~15~H~24~O~3~, as that of **4**. By analysis of 2D NMR spectra, including ^1^H-^1^H COSY, HMQC, and HMBC, compound **5** was shown to possess the same molecular framework as that of **4**. Comparison of the NMR data of **5** with those of **4** revealed that the only difference between the compounds was the replacement of the β-hydroperoxy group at C-1 in **4** by the α-hydroperoxy group in **5**. From the NOESY spectrum, it was found both protons of H~2~-2 (each 1H, δ 2.19 and 2.24, m) showed NOE interactions with one of the sp^2^methylene proton at C-14 (δ 4.97, s), suggesting the α-orientation of 1-OOH by investigation of the molecular model ([Figure 3](#marinedrugs-10-01572-f003){ref-type="fig"}). Further analysis of other NOE interactions revealed that **5** possesses the same relative configurations at C-4, C-5, C-6, and C-7, as those of **4**. Therefore, **5**was found to be the C-1 epimer of **4**.

Lochmolin F (**6**) was obtained as a colorless oil and exhibited an ion peak at *m/z* 236.1774 (\[M\]^+^) by HREIMS, appropriate for the molecular formula C~15~H~24~O~2~. Comparison of the NMR data of **6** with those of **3** revealed that the only difference between both compounds was the replacement of a hydroperoxy group at C-10 in **3** by the hydroxy moiety in **6**. This was evidenced from the upfield chemical shifts induced by a hydroxy group at C-10 (δc 73.9) and H~3~-14 (δ~H~ 1.32) in **6** relative to those of **3**. The relative configuration of **6** was determined by analysis of key NOE correlations ([Figure 3](#marinedrugs-10-01572-f003){ref-type="fig"}).

The metabolite lochmolin G (**7**) was also obtained as a colorless oil. Its HRESIMS spectroscopic data (*m/z* 261.1828) suggested the molecular formula C~15~H~26~O~2~, requiring three degrees of unsaturation. IR absorption was observed at 3303 cm^−1^, suggesting the presence of hydroxy group in **7**. In the ^13^C NMR and DEPT spectra ([Table 1](#marinedrugs-10-01572-t001){ref-type="table"}), signals of four methyls, four sp^3^methylenes, one sp^3^methine, three sp^2^methines, two sp^3^ quaternary carbons, and one sp^2^ quaternary carbons were observed. The ^13^C NMR data of **7** ([Table 1](#marinedrugs-10-01572-t001){ref-type="table"}) revealed the presence of one trisubstituted and one 1,2-disubstituted carbon-carbon double bond \[δc 131.9 (C) and 129.5 (CH); 143.1 (CH) and 128.4 (CH)\]. Two hydroxylated carbons (δc 73.0 and 71.9) were also assigned from the ^13^C NMR spectrum. The remaining one degree of unsaturation identified **7** as a cyclic compound. The planar structure of metabolite **7** was elucidated by analysis of ^1^H-^1^H COSY and HMBC correlations ([Figure 1](#marinedrugs-10-01572-f001){ref-type="fig"}). Key HMBC correlations from H~3~-12 to C-7, C-11, and C-13; H~3~-13 to C-7, C-11, and C-12; H~3~-14 to C-1, C-9, and C-10; H~3~-15 to C-3, C-4, and C-5 permitted the establishment of the germacrane skeleton. In the NOESY spectrum of **7** ([Figure 4](#marinedrugs-10-01572-f004){ref-type="fig"}), observation of the NOE correlations between H-6 and H~3~-12, H~3~-13 and H~3~-15, and between H-5 and H-7, suggested that H~3~-15 is α-oriented, and H-7 is β-oriented. The *E* geometries were assigned for the 5,6- and 9,10- double bonds on the basis of the upfield chemical shift of C-14 (δ 16.6) and the large coupling constant between H-5 and H-6 (*J* = 16.0 Hz). Therefore, the relative structure of **7** was established.
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###### 

^1^H NMR spectral data for compounds **5**--**7**.

          5                     6                          7
  ------- --------------------- -------------------------- ----------------------
  1                                                        2.24 m
                                                           2.29 m
  2       2.19 m                5.54 dd (3.0, 1.5) *^a^*   1.61 m
          2.24 m                                           
  3       1.78 m                2.25 dd (16.5, 3.0)        1.65 m
          1.98 m                2.55 d (16.5)              1.70 m
  5       1.75 d (12.0)         1.96 d (10.0)              5.44 d (16.0)
  6       0.50 dd (12.0, 9.5)   0.29 dd (10.0, 9.5)        5.13 dd (16.0, 10.0)
  7       0.81 m                0.57 m                     2.23 m
  8       0.99 m                0.98 m                     2.07 m
          2.08 m                1.90 m                     2.27 m
  9       2.32 dd (13.0, 6.5)   1.59 m                     4.90 brd (11.5)
          2.44 t (13.0)         1.89 m                     
  12      1.07 s                1.03 s                     1.11 s
  13      1.01 s                1.08 s                     1.16 s
  14      4.97 s                1.32 s                     1.53 s
          4.99 s                                           
  15      1.33 s                1.37 s                     1.37 s
  1-OOH   7.06 s                                           

*^a^* *J* values (Hz) in parentheses.

![Key NOESY correlations for 7.](marinedrugs-10-01572-g004){#marinedrugs-10-01572-f004}

Cytotoxicity of compounds **1**--**7** against the proliferation of a limited panel of cancer cell lines, including human cervical epitheloid (HeLa), liver (SK-Hep1), and melanin (B-16) carcinoma cells, was evaluated. The results showed all of compounds were not cytotoxic toward these three cancer cell lines. The anti-inflammatory activities of **1**--**7** against the accumulation of pro-inflammatory iNOS and COX-2 proteins in RAW264.7 macrophage cells were evaluated by Western blot analysis. It was found that **1**--**7** could not reduce the accumulation of iNOS protein induced by LPS. At a concentration of 1 μM, only compound **1** could reduce the level of LPS-induced COX-2 to 36.6 ± 3.8%. At a concentration of 10 μM, compounds **1**, **3**, and **4** reduced the accumulation of LPS-induced COX-2 to 8.7 ± 4.5%, 61.0 ± 6.0%, and 83.4 ± 6.4%, respectively. At a concentration of 100 μM, **1**--**4** could further reduce the levels of induced COX-2 to 1.7 ± 1.3%, 17.6 ± 2.2%, 32.8 ± 3.2%, and 71.3 ± 7.2%, respectively, in comparison with those of control cells stimulated with LPS only. Thus, compound **1** might be considered to be a promising COX-2 inhibiting agent.

3. Experimental Section
=======================

3.1. General Experimental Procedures
------------------------------------

Optical rotations were measured on a JASCO P-1020 polarimeter. IR spectra were recorded on a JASCO FT/IR-4100 infrared spectrophotometer. The NMR spectra were recorded on a Varian Unity INOVA 500 FT-NMR at 500 MHz for ^1^H and 125 MHz for ^13^C, in CDCl~3~ using TMS as internal standard. LRMS and HRMS were obtained by ESI on a Bruker APEX ΙΙ mass spectrometer, or by EI on a JEOL-SX/SX 102A mass spectrometer. Silica gel 60 (Merck, 230--400 mesh) was used for column chromatography. Precoated silica gel plates (Merck, Kieselgel 60 F~254~, 0.2 mm) were used for analytical TLC. High-performance liquid chromatography was performed on a Hitachi L-6250 HPLC apparatus with a merck Hibar Si-60 column (250 × 21 mm, 7 μm).

3.2. Animal Material
--------------------

*Sinularia lochmodes* was collected by hand using SCUBA off the northeast corner of Taiwan, in May 2004, at a depth of 10 to 15 m, and stored in a freezer until extraction. A voucher sample was deposited at the Department of Marine Biotechnology and Resources, National Sun Yat-sen University (specimen No. 20040516-3).

3.3. Extraction and Separation
------------------------------

The frozen bodies of *S. lochmodes* (139.4 g) were minced and extracted with ethyl acetate. The organic extract (4.87 g) of the organsim was fractionated by silica gel column chromatography to afford 22 fractions (Fractions A to V). Fraction D, eluted with *n*-hexane--EtOAc (60:1), was purified by normal-phase HPLC (*n*-hexane--EtOAc, 60:1) to afford **1** (3.5 mg). Fraction G, eluted with *n*-hexane--EtOAc (20:1), was purified by normal-phase HPLC (*n*-hexane--EtOAc, 30:1) to afford **2** (1.5 mg). Fraction K, eluted with *n*-hexane--EtOAc (2:1), was purified by normal-phase HPLC (*n*-hexane--EtOAc, 3:1) to afford **3** (2.4 mg), **4** (1.2 mg), and **5** (2.0 mg). Fraction M, eluted with *n*-hexane--EtOAc (1:2), was purified by normal-phase HPLC (*n*-hexane--EtOAc, 1:1) to afford **6** (1.6 mg), and **7** (4.2 mg).

Lochmolin A (**1**): colorless oil; \[α\]^26^~D~ = −89 (*c* 0.5, CHCl~3~); ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-10-01572-t001){ref-type="table"} and [Table 2](#marinedrugs-10-01572-t002){ref-type="table"}; EIMS (70 eV) *m*/*z* 234 \[M\]^+^; HREIMS *m*/*z* 234.1620 (calcd for C~15~H~22~O~2~, 234.1621).

Lochmolin B (**2**): colorless oil; \[α\]^26^~D~ = −173 (*c* 0.8, CHCl~3~); IR (neat, CHCl~3~) ν~max~ 3437 (broad) cm^−1^; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-10-01572-t001){ref-type="table"} and [Table 2](#marinedrugs-10-01572-t002){ref-type="table"}; ESIMS *m*/*z* 289 \[M + Na\]^+^; HRESIMS *m*/*z* 289.2147 (calcd for C~17~H~30~O~2~Na, 289.2143).

Lochmolin C (**3**): colorless oil; \[α\]^26^~D~ = −261 (*c* 0.6, CHCl~3~); IR (neat, CHCl~3~) ν~max~ 3437 (broad) cm^−1^; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-10-01572-t001){ref-type="table"} and [Table 2](#marinedrugs-10-01572-t002){ref-type="table"}; ESIMS *m*/*z* 275 \[M + Na\]^+^; HRESIMS *m*/*z* 275.1622 (calcd for C~15~H~24~O~3~Na, 275.1623).

Lochmolin D (**4**): colorless oil; \[α\]^26^~D~ = −66 (*c* 2.0, CHCl~3~); IR (neat, CHCl~3~) ν~max~ 3406 (broad) cm^−1^; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-10-01572-t001){ref-type="table"} and [Table 2](#marinedrugs-10-01572-t002){ref-type="table"}; ESIMS *m*/*z* 275 \[M + Na\]^+^; HRESIMS *m*/*z* 275.1622 (calcd for C~15~H~24~O~3~Na, 275.1623).

Lochmolin E (**5**): colorless oil; \[α\]^26^~D~ = −66 (*c* 2.0, CHCl~3~); IR (neat, CHCl~3~) ν~max~ 3448 (broad) cm^−1^; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-10-01572-t001){ref-type="table"} and [Table 3](#marinedrugs-10-01572-t003){ref-type="table"}; ESIMS *m*/*z* 275 \[M + Na\]^+^; HRESIMS *m*/*z* 275.1623 (calcd for C~15~H~24~O~3~Na, 275.1621).

Lochmolin F (**6**): colorless oil; \[α\]^26^~D~ = −75 (*c* 0.7, CHCl~3~); IR (neat, CHCl~3~) ν~max~ 3396 (broad) cm^−1^; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-10-01572-t001){ref-type="table"} and [Table 3](#marinedrugs-10-01572-t003){ref-type="table"}; EIMS (70eV) *m*/*z* 236 \[M\]^+^; HREIMS *m*/*z* 236.1774 (calcd for C~15~H~24~O~2~, 236.1777).

Lochmolin G (**7**): colorless oil; \[α\]^26^~D~ = −42 (*c* 0.55, CHCl~3~); IR (neat, CHCl~3~) ν~max~ 3303 (broad) cm^−1^; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-10-01572-t001){ref-type="table"} and [Table 3](#marinedrugs-10-01572-t003){ref-type="table"}; ESIMS *m*/*z* 261 \[M + Na\]^+^; HRESIMS *m*/*z* 261.1828 (calcd for C~15~H~26~O~2~Na, 261.1830).

3.4. Cytotoxicity Testing
-------------------------

Cell lines were purchased from the American Type Culture Collection (ATCC). Cytotoxicity assays of compounds **1**--**7** were performed using the Alamar Blue assay \[[@B9-marinedrugs-10-01572],[@B10-marinedrugs-10-01572]\].

3.5. **In Vitro** Anti-Inflammatory Assay
-----------------------------------------

Murine RAW264.7 macrophages were purchased from the American Type Culture Collection. The anti-inflammatory assay was modified from known procedure \[[@B11-marinedrugs-10-01572],[@B12-marinedrugs-10-01572],[@B13-marinedrugs-10-01572]\].

4. Conclusions
==============

Our present investigation again demonstrated that the Formosan soft coral *Sinularia lochmodes* is a good source of bioactive substances. In our investigation of new and bioactive metabolites from the Formosan soft corals, this is the first study of *S. lochmodes* collected from the northeast corner of Taiwan. The aromadendrane-type compounds **1**--**4**, in particular **1**, might become a promising COX-2 inhibiting agent.
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